Oncology Department, Medical University of Warsaw, 19/25 Stępińska St., 00-739, Warsaw, Poland.
Patomorphology Department, Military Institute of Medicine, 128 Szaserów St., 04-141, Warsaw, Poland.
Pathol Oncol Res. 2020 Apr;26(2):1211-1219. doi: 10.1007/s12253-019-00678-1. Epub 2019 Jun 19.
The aim of the study was to determine the prognostic value of expression levels of biomarkers selected on the basis of the literature: p53, Ki-67, survivin, β-catenin, E-cadherin and N-cadherin in patients with non-muscle invasive bladder cancer. Immunohistochemistry was performed on sections of primary papillary carcinoma of the bladder removed during transurethral resection of the tumor in 134 patients. The expression of β-catenin and E-cadherin was found in all analyzed cases and N-cadherin expression was demonstrated in 3.73% of the tissues examined. The expression of the p53 protein was confirmed in 96.27% of tissues examined. The expression of the Ki-67 protein was demonstrated in all analyzed cases. Survivin expression was found in 95.52% of the study group. Multivariate analysis confirmed the relationship between the recurrence-free survival (RFS) and the intensity of the nuclear reaction for p53 (HR 1417, 95% CI 1.001-2.007, p = 0.049) and survivin (HR 1.451; 95% CI 1.078-1.955; p = 0.014), the expression level of the Ki-67 protein expressed by the TS index (HR 1.146, 95% CI 1.116-1.823, p = 0.005) and the use of adjuvant BCG therapy (HR 0.218, 95% CI 0.097-0.489, p = 0.0002). The evaluation of Ki-67 expression and the intensity of nuclear staining for survivin and p53 may provide additional information that will allow more accurate stratification of the risk of NMIBC recurrence after TURBT.
p53、Ki-67、存活素、β-连环蛋白、E-钙黏蛋白和 N-钙黏蛋白。对 134 例经尿道肿瘤切除术切除的原发性膀胱乳头状癌标本进行免疫组织化学染色。在所有分析的病例中均发现β-连环蛋白和 E-钙黏蛋白的表达,在 3.73%的检查组织中显示 N-钙黏蛋白的表达。在 96.27%的检查组织中证实了 p53 蛋白的表达。所有分析病例均显示 Ki-67 蛋白的表达。在研究组中发现 95.52%的生存素表达。多变量分析证实无复发生存(RFS)与 p53 核反应强度(HR 1417,95%CI 1.001-2.007,p=0.049)和生存素(HR 1.451;95%CI 1.078-1.955;p=0.014)之间存在相关性,Ki-67 蛋白表达水平(TS 指数 HR 1.146,95%CI 1.116-1.823,p=0.005)和辅助 BCG 治疗的使用(HR 0.218,95%CI 0.097-0.489,p=0.0002)。Ki-67 表达和核染色强度的评估,以及生存素和 p53 的表达,可能提供额外的信息,有助于更准确地分层 TURBT 后非肌肉浸润性膀胱癌复发的风险。